MetaVia Advances Next-Gen Obesity Drug DA-1726 Into Higher-Dose Trial Phase

MetaVia Advances Next-Gen Obesity Drug DA-1726 Into Higher-Dose Trial Phase

By, Admin 11 April 2026

The GLP-1 race is evolving—and the next wave is already here. MetaVia Inc. has dosed the first patient in Part 3 of its Phase 1 trial for DA-1726, a next-generation obesity drug designed to go beyond traditional GLP-1 therapies.

The goal? Better weight loss, faster dosing, and improved tolerability.

What Makes DA-1726 Different?

Most current obesity drugs target a single pathway. DA-1726 takes a dual approach.

Mechanism of Action

  • Activates GLP-1 receptors (GLP1R) → reduces appetite
  • Activates glucagon receptors (GCGR) → increases energy expenditure

Why This Matters?

This combination aims to:

  • Enhance weight loss outcomes
  • Improve metabolic health
  • Potentially outperform single-pathway drugs

The Trial: Designed to Push Higher Doses Faster

Part 3 of the Phase 1 study focuses on a critical challenge in obesity drugs: How do you reach effective doses without triggering side effects?

Study Design

  • 40 obese, otherwise healthy adults
  • Two cohorts (20 patients each, 4:1 randomization)

Two Titration Strategies

Part 3A (One-Step):

  • 16 mg for 4 weeks
  • Jump to 48 mg for 12 weeks

Part 3B (Two-Step):

  • 16 mg → 32 mg → 64 mg
  • Gradual escalation over 16 weeks

What’s Being Measured

  • Safety and tolerability (AEs, SAEs, discontinuations)
  • Pharmacokinetics (PK) and pharmacodynamics (PD)
  • Weight, BMI, waist circumference
  • Glycemic and lipid markers

Topline data is expected in Q4 2026.

Early Signals: Why Investors Are Watching

The excitement isn’t hypothetical. Earlier Phase 1 data already showed:

  • ~9% weight loss at 48 mg
  • Reduced waist circumference
  • Improved glucose control
  • Early signs of liver benefit

And importantly:

  • Favorable tolerability profile

How It Stacks Up Against Current Leaders

The obesity drug market is dominated by GLP-1 therapies like:

  • Wegovy (semaglutide)
  • Zepbound (tirzepatide)

Where DA-1726 Could Win

  • Dual mechanism: potentially stronger weight loss
  • Higher-dose tolerance: faster results
  • Lean mass preservation:  better quality outcomes

Preclinical data even suggests:

  • Comparable or better weight loss vs GLP-1 drugs
  • Improved lipid effects
  • Maintained muscle mass

Beyond Weight Loss: The MASH Opportunity

DA-1726 isn’t just an obesity drug.  It’s also being developed for:

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Why This Matters

MASH is:

  • A growing global health burden
  • Closely linked to obesity and metabolic disease
  • Still lacking widely effective treatments

If DA-1726 delivers here, it could unlock a second major market.

The Bigger Strategy: Redefining the Next Wave of GLP-1 Therapies

The first wave of GLP-1 drugs proved demand. Now companies are optimizing for:

  • Greater efficacy
  • Faster titration
  • Better tolerability
  • Broader metabolic benefits

MetaVia Inc. is positioning DA-1726 squarely in this next phase.

Final Take

This is still early-stage. But the direction is clear. If Part 3 confirms:

  • Strong weight loss
  • Manageable side effects
  • Faster path to optimal dosing

Then DA-1726 could emerge as a serious contender in the post-GLP-1 era. For now, all eyes are on Q4 2026.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!